Alzheimer's Treatment Shows Promise Amid NIH Funding Delays

An experimental Alzheimer's treatment, led by Washington University in St. Louis, has shown promising results in delaying symptoms in individuals genetically predisposed to the disease. The research, published in Lancet Neurology, indicates that long-term amyloid removal can significantly reduce the risk of symptom onset. However, the ongoing study faces significant challenges due to funding delays from the United States — National Institutes of Health, which has stalled millions of dollars in research. This situation has raised concerns among participants and researchers, especially with the nomination of Jay Bhattacharya as the new director of the United States — National Institutes of Health, who has expressed views on broadening research hypotheses beyond amyloid. The potential loss of funding could jeopardize the opportunity to determine the long-term effectiveness of these treatments, impacting the future of Alzheimer's care.